Literature DB >> 24954011

Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Irfana Muqbil1, Jack Wu1, Amro Aboukameel1, Ramzi M Mohammad2, Asfar S Azmi3.   

Abstract

Epithelial-to-mesenchymal transition (EMT) and the reverse process (MET) play central role in organ developmental biology. It is a fine tuned process that when disturbed leads to pathological conditions especially cancers with aggressive and metastatic behavior. Snail is an oncogene that has been well established to be a promoter of EMT through direct repression of epithelial morphology promoter E-cadherin. It can function in the nucleus, in the cytosol and as discovered recently, extracellularly through secretory vesicular structures. The intracellular transport of snail has for long been shown to be regulated by the nuclear pore complex. One of the Karyopherins, importin alpha, mediates snail import, while exportin 1 (Xpo1) also known as chromosome maintenance region 1 (CRM1) is its major nuclear exporter. A number of additional biological regulators are emerging that directly modulate Snail stability by altering its subcellular localization. These observations indicate that targeting the nuclear transport machinery could be an important and as of yet, unexplored avenue for therapeutic intervention against the EMT processes in cancer. In parallel, a number of novel agents that disrupt nuclear transport have recently been discovered and are being explored for their anti-cancer effects in the early clinical settings. Through this review we provide insights on the mechanisms regulating snail subcellular localization and how this impacts EMT. We discuss strategies on how the nuclear transport function can be harnessed to rein in EMT through modulation of snail signaling.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRM1; EMT; Karyopherin; Nuclear transport; Xpo1

Mesh:

Substances:

Year:  2014        PMID: 24954011      PMCID: PMC4165636          DOI: 10.1016/j.semcancer.2014.06.003

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  67 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 2.  The ins and outs of the epithelial to mesenchymal transition in health and disease.

Authors:  M Angela Nieto
Journal:  Annu Rev Cell Dev Biol       Date:  2011-07-08       Impact factor: 13.827

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Y Zhong; D El-Gamal; J A Dubovsky; K A Beckwith; B K Harrington; K E Williams; V M Goettl; S Jha; X Mo; J A Jones; J M Flynn; K J Maddocks; L A Andritsos; D McCauley; S Shacham; M Kauffman; J C Byrd; R Lapalombella
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

5.  Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail.

Authors:  Cheng Du; Chuanyou Zhang; Sazzad Hassan; Md Helal Uddin Biswas; K C Balaji
Journal:  Cancer Res       Date:  2010-10-12       Impact factor: 12.701

6.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

7.  CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.

Authors:  Roberto A Salas Fragomeni; Hye Won Chung; Yosef Landesman; William Senapedis; Jean-Richard Saint-Martin; Hensin Tsao; Keith T Flaherty; Sharon Shacham; Michael Kauffman; James C Cusack
Journal:  Mol Cancer Ther       Date:  2013-04-24       Impact factor: 6.261

8.  CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

Authors:  Hiromi Inoue; Michael Kauffman; Sharon Shacham; Yosef Landesman; Joy Yang; Christopher P Evans; Robert H Weiss
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

9.  Importin beta-depending nuclear import pathways: role of the adapter proteins in the docking and releasing steps.

Authors:  Christiane Rollenhagen; Petra Mühlhäusser; Ulrike Kutay; Nelly Panté
Journal:  Mol Biol Cell       Date:  2003-02-06       Impact factor: 4.138

10.  Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25.

Authors:  Asfar S Azmi; Aliccia Bollig-Fischer; Bin Bao; Bum-Joon Park; Sun-Hye Lee; Gyu Yong-Song; Gregory Dyson; Chandan K Reddy; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  BMC Syst Biol       Date:  2013-09-03
View more
  33 in total

1.  NQO1 downregulation potentiates menadione-induced endothelial-mesenchymal transition during rosette formation in Fuchs endothelial corneal dystrophy.

Authors:  Kishore Reddy Katikireddy; Tomas L White; Taiga Miyajima; Shivakumar Vasanth; Duna Raoof; Yuming Chen; Marianne O Price; Francis W Price; Ula V Jurkunas
Journal:  Free Radic Biol Med       Date:  2017-12-30       Impact factor: 7.376

Review 2.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

3.  PP2A protects podocytes against Adriamycin-induced injury and epithelial-to-mesenchymal transition via suppressing JIP4/p38-MAPK pathway.

Authors:  Zhihong Lu; Xiujuan Zhu; Yuhong Ye; Haidong Fu; Jianhua Mao
Journal:  Cytotechnology       Date:  2021-08-13       Impact factor: 2.040

4.  Synergistic effects of snail and quercetin on renal cell carcinoma Caki-2 by altering AKT/mTOR/ERK1/2 signaling pathways.

Authors:  Fan-Dong Meng; Yan Li; Xin Tian; Ping Ma; Cheng-Guang Sui; Li-Ye Fu; You-Hong Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

5.  SATB1 protein is associated with the epithelial‑mesenchymal transition process in non‑small cell lung cancers.

Authors:  Natalia Glatzel-Plucinska; Aleksandra Piotrowska; Adam Rzechonek; Marzenna Podhorska-Okolow; Piotr Dziegiel
Journal:  Oncol Rep       Date:  2021-05-06       Impact factor: 3.906

6.  Claudin-7 promotes the epithelial-mesenchymal transition in human colorectal cancer.

Authors:  Rahel Philip; Sarah Heiler; Wei Mu; Markus W Büchler; Margot Zöller; Florian Thuma
Journal:  Oncotarget       Date:  2015-02-10

7.  Left-right axis asymmetry determining human Cryptic gene is transcriptionally repressed by Snail.

Authors:  Kartik Gupta; Vijaya Satish Sekhar Pilli; Gopala Krishna Aradhyam
Journal:  BMC Dev Biol       Date:  2016-10-28       Impact factor: 1.978

8.  TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway.

Authors:  Li Qi; Zhong Lu; Yong-Hong Sun; Hai-Tao Song; Wei-Kang Xu
Journal:  Int J Mol Med       Date:  2016-10-17       Impact factor: 4.101

9.  ESRRA promotes gastric cancer development by regulating the CDC25C/CDK1/CyclinB1 pathway via DSN1.

Authors:  Feng-Nan Li; Qin-Yi Zhang; Ou Li; Shi-Lei Liu; Zi-Yi Yang; Li-Jia Pan; Cheng Zhao; Wei Gong; Yi-Jun Shu; Ping Dong
Journal:  Int J Biol Sci       Date:  2021-05-10       Impact factor: 6.580

10.  Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Authors:  Asfar S Azmi; Irfana Muqbil; Jack Wu; Amro Aboukameel; William Senapedis; Erkan Baloglu; Aliccia Bollig-Fischer; Gregory Dyson; Michael Kauffman; Yosef Landesman; Sharon Shacham; Philip A Philip; Ramzi M Mohammad
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.